An association between accelerated atherosclerosis and systemiclupus erythematosus (SLE), typified by the occurrence of a myocardialinfarction in a 30-year-old woman who had had the disease formore than 10 years, was suggested in 1976.1 The two studiesby Roman et al. (pages 2399–2406) and Asanuma et al. (pages2407–2415) in this issue of the Journal confirm this associationand provide important information regarding risk factors. Thereported prevalence of myocardial infarcts in patients withSLE ranges from 4 percent to 45 percent, with studies of surrogatemarkers providing support for the higher figure. For example,in one study . . . [Full Text of this Article]
Source Information
From the David Geffen School of Medicine at the University of California Los Angeles, Los Angeles.
Related Letters:
Premature Coronary Disease in Systemic Lupus
Wurzel J., Goldman B. I., Doria A., Shoenfeld Y., Pauletto P., Violi F., Loffredo L., Ferro D., Pezzetta F., Mascitelli L., Noël B., Roman M. J., Lockshin M. D., Salmon J. E., Stein C. M., Hahn B. H.
Extract |
Full Text |
PDF
N Engl J Med 2004;
350:1571-1575, Apr 8, 2004.
Correspondence
This article has been cited by other articles:
Sabio, J., Zamora-Pasadas, M, Jimenez-Jaimez, J, Albadalejo, F, Vargas-Hitos, J, Rodriguez del Aguila, M., Hidalgo-Tenorio, C, Gonzalez-Gay, M., Alonso, J.
(2008). Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus
17: 849-859
[Abstract]
Martinez-Berriotxoa, A., Ruiz-Irastorza, G., Egurbide, M.-V., Garmendia, M., Gabriel Erdozain, J., Villar, I., Aguirre, C.
(2007). Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus
16: 810-816
[Abstract]
Avalos, I, Chung, C P, Oeser, A, Milne, G L, Morrow, J D, Gebretsadik, T, Shintani, A, Yu, C, Stein, C M
(2007). Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus
16: 195-200
[Abstract]
Sinclair, A, Baildon, R
(2006). Mycophenolate mofetil: an overview. Lupus
15: 70-77
Rahman, A, Bessant, R, Isenberg, D A
(2006). What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus?. Lupus
15: 697-699
Ruiz-Irastorza, G, Egurbide, M-V, Pijoan, J-I, Garmendia, M, Villar, I, Martinez-Berriotxoa, A, Erdozain, J-G, Aguirre, C
(2006). Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus
15: 577-583
[Abstract]
Allison, A C
(2005). Mechanisms of action of mycophenolate mofetil. Lupus
14: s2-s8
[Abstract]
Jadoul, M
(2005). Optimal care of lupus nephritis patients. Lupus
14: 72-76
[Abstract]
Allison, A.
(2005). Mechanisms of action of mycophenolate mofetil. Lupus
14: s2-s8
[Abstract]
Houssiau, F. A.
(2004). Management of Lupus Nephritis: An Update. J. Am. Soc. Nephrol.
15: 2694-2704
[Full Text]
Stefanec, T.
(2004). Endothelial apoptosis: the missing link between atherosclerosis and SLE?. Blood
103: 3608-3609
[Full Text]
Wurzel, J., Goldman, B. I., Doria, A., Shoenfeld, Y., Pauletto, P., Violi, F., Loffredo, L., Ferro, D., Pezzetta, F., Mascitelli, L., Noel, B., Roman, M. J., Lockshin, M. D., Salmon, J. E., Stein, C. M., Hahn, B. H.
(2004). Premature Coronary Disease in Systemic Lupus. NEJM
350: 1571-1575
[Full Text]
